Akari Therapeutics (FRA:CLA) Beginning Cash Position : €3.76 Mil (As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Akari Therapeutics Beginning Cash Position?

Akari Therapeutics's Beginning Cash Position for the quarter that ended in Sep. 2024 was €3.76 Mil.

Akari Therapeutics's quarterly Beginning Cash Position declined from Mar. 2024 (€3.54 Mil) to Jun. 2024 (€1.22 Mil) but then increased from Jun. 2024 (€1.22 Mil) to Sep. 2024 (€3.76 Mil).

Akari Therapeutics's annual Beginning Cash Position declined from Dec. 2021 (€12.44 Mil) to Dec. 2022 (€8.84 Mil) but then increased from Dec. 2022 (€8.84 Mil) to Dec. 2023 (€12.15 Mil).

Akari Therapeutics Beginning Cash Position Historical Data

The historical data trend for Akari Therapeutics's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akari Therapeutics Beginning Cash Position Chart

Akari Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

5.37

4.71

12.44

8.84

12.15

Akari Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beginning Cash Position	Get a 7-Day Free Trial															6.73	4.34	3.54	1.22	3.76

Akari Therapeutics Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Akari Therapeutics Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Akari Therapeutics's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Akari Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akari Therapeutics PLC (FRA:CLA) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

AKTX:USA

Address

22 Boston Wharf Road, Boston, MA, USA, 02210

Website

https://www.akaritx.com

Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).